Incyte claims double Phase 3 win in vitiligo, will file for approval
Incyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · health
- [HEALTH] From crisis to commitment: nursing students' sense of belonging during and immediately after the covid-19 pandemic.
- [HEALTH] In the name of immunity, for the sake of the sacred: An analysis of the Iranian government's response to the COVID-19 ou
- [HEALTH] Knowledge, Attitudes, and Practices Regarding Arboviruses at a Human-Wildlife Interface: A Cross-Sectional Study in and
- [HEALTH] How to shore up trust during the "cold-period" between pandemics - closing the public trust gap in pandemic preparedness
- [HEALTH] Artificial intelligence at the frontlines: Emerging infectious and parasitic diseases in the digital era.
- [HEALTH] Emergency department evaluation and management of serious and high-risk infections in the febrile returning traveler.